Literature DB >> 31419490

Safety of direct drug provocation testing in adults with penicillin allergy and association with health and economic benefits.

Jamma Li1, Aryan Shahabi-Sirjani2, Melanie Figtree3, Philip Hoyle4, Suran L Fernando5.   

Abstract

BACKGROUND: Nonprescription of penicillin-containing antibiotics in patients diagnosed with penicillin allergy is associated with morbidity and mortality. Adverse reactions to penicillins comprise type A and B reactions.
OBJECTIVE: To assess the feasibility of penicillin allergy evaluation without penicillin skin testing (PST) for adult patients with type B reactions and the health and economic benefits of this process.
METHODS: Inpatients at an Australian tertiary hospital between April 1, 2017, and April 30, 2018, with a diagnosis of type B penicillin allergy, requiring a penicillin-containing antibiotic for treatment, were included. All patients underwent clinical history review, PST, and drug provocation testing (DPT).
RESULTS: Seventy-one patients were enrolled. Sixty-three reported a history of type B or unknown adverse reactions. No patients had a history of anaphylaxis requiring intubation or epinephrine within the last 10 years or a history suggesting Gell and Coombs type 2, 3, or 4 (severe) hypersensitivity reaction. Seven did not complete DPT because the treating team used a β-lactam antibiotic other than amoxicillin. Fifty-four of 56 remaining patients (96%) completed 3-day DPT to amoxicillin with no adverse reaction. Two experienced mild cutaneous reactions. Penicillin allergy evaluation was significantly associated with reduced length of stay, reduced hospital expenditure on bed and second-line antibiotics, and reduced readmission rates.
CONCLUSION: Penicillin allergy evaluation with DPT without PST may be feasible for all adult patients with a reported history of type B reactions to penicillins who do not have a history of anaphylaxis within the last 10 years or a type 2, 3, or 4 (severe) hypersensitivity reaction.
Copyright © 2019 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31419490     DOI: 10.1016/j.anai.2019.08.005

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  4 in total

1.  Penicillin Allergy Testing Is Cost-Saving: An Economic Evaluation Study.

Authors:  Bernardo Sousa-Pinto; Kimberly G Blumenthal; Eric Macy; Ana Margarida Pereira; Luís Filipe Azevedo; Luís Delgado; João Almeida Fonseca
Journal:  Clin Infect Dis       Date:  2021-03-15       Impact factor: 9.079

2.  The Penicillin Allergy Delabeling Program: A Multicenter Whole-of-Hospital Health Services Intervention and Comparative Effectiveness Study.

Authors:  Kyra Y L Chua; Sara Vogrin; Susan Bury; Abby Douglas; Natasha E Holmes; Nixon Tan; Natasha K Brusco; Rebecca Hall; Belinda Lambros; Jacinta Lean; Wendy Stevenson; Misha Devchand; Kent Garrett; Karin Thursky; M Lindsay Grayson; Monica A Slavin; Elizabeth J Phillips; Jason A Trubiano
Journal:  Clin Infect Dis       Date:  2021-08-02       Impact factor: 9.079

Review 3.  Safety and efficacy of de-labelling penicillin allergy in adults using direct oral challenge: a systematic review.

Authors:  Lesley Cooper; Jenny Harbour; Jacqueline Sneddon; R Andrew Seaton
Journal:  JAC Antimicrob Resist       Date:  2021-01-27

Review 4.  Drug hypersensitivity reactions in Asia: regional issues and challenges.

Authors:  Bernard Yu-Hor Thong; Michaela Lucas; Hye-Ryun Kang; Yoon-Seok Chang; Philip Hei Li; Min Moon Tang; James Yun; Jie Shen Fok; Byung-Keun Kim; Mizuho Nagao; Iris Rengganis; Yi-Giien Tsai; Wen-Hung Chung; Masao Yamaguchi; Ticha Rerkpattanapipat; Wasu Kamchaisatian; Ting Fan Leung; Ho Joo Yoon; Luo Zhang; Amir Hamzah Abdul Latiff; Takao Fujisawa; Francis Thien; Mariana C Castells; Pascal Demoly; Jiu-Yao Wang; Ruby Pawankar
Journal:  Asia Pac Allergy       Date:  2020-01-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.